Wikipedia -WSS

Wikipedia

author：knowledge 2025-10-02 19:15:44 - browse：875

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： This gene therapy has record $4.25 million price. It's saved children.

hotspot

explore

WSS

U.K. officials, researchers try to ease path for bespoke genetic treatments

Yancopoulos of Regeneron works to expand Dupixent success

Sage's campaign to raise awareness of postpartum depression hits a nerve

Astronauts get first look at the spacecraft that will fly them around the moon

Wegovy cuts risk of cardiovascular events by 20%, study finds

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Walensky prepares to leave CDC — and Congress — behind

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Anesthesiologist group: stop taking Ozempic before surgery

Readout LOUD podcast, live from the STAT Breakthrough Summit East

How one medical school became remarkably diverse

Travel bans should be based on evidence, not politics or fear

Peter Hotez and the public health issue of online harassment

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

DIEP, the 'gold standard' of breast reconstruction, is under threat

Chinese researcher claims birth of first gene

explore

Judge rejects Trump's counterclaim against E. Jean Carroll

Adam's Take: Intra

‘The Bear’ and hospitality in hospitals

An Ebola outbreak presents a new mystery involving children

Pregnancy ages women, but effects reverse after delivery

Steward Health Care expansion into Malta flopped

hotspot

hotspot

explore

hotspot